PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 9 | 6 | 796-801
Article title

Eosinophilia-myalgia syndrome induced by excessive L-tryptophan intake from cashew nuts

Content
Title variants
Languages of publication
EN
Abstracts
EN
Eosinophilia is characterized by more than 0.5 × 109 eosinophils per liter in the full blood count. A wide range of conditions, from asthma to parasitic infections, autoimmune diseases, and certain forms of cancer, have been known to trigger abnormally high amount of eosinophils. It is essential to reach the correct diagnosis and treat the underlying disease aggresively. Definition of the eosinophilia-myalgia syndrome was offered in 1980s by Centers for Disease Control and Prevention for surveillance purposes, and criteria were revised in 2001, with high specificity. We report a case of 59-year old female who started a special weight-reducing diet regimen that included excessive cashew nut ingestion. Several months after she has presented with periferal blood eosinophilia and constitutional symptoms. Detailed work-up has not found elements for haematological, systemic autoimmune, neoplastic or infectious disease. She was diagnosed with eosinophilia-myalgia syndrome due to extreme L-tryptophan intake, a compound found in the cashew nut’s oil. She responded well to cashew nut withdrawal and steroid therapy. In the follow-up period she remained stable with normal eosinophil count and there was not a need for any specific therapy.
Publisher
Journal
Year
Volume
9
Issue
6
Pages
796-801
Physical description
Dates
published
1 - 12 - 2014
online
16 - 8 - 2014
References
  • [1] Holland SM, Gallin JI. Disorders of Granulocytes and Monocytes. In: Fauci AS et al. [ed.] Harrison’s Principles of Internal Medicine, ed. 17. New York, McGraw-Hill Companies, 2008:383
  • [2] Medsger, T.A. Eosinophilia-myalgia syndrome. In Medscape Reference [online]. Available at: www.emedicine.medscape.com/article/329614-overview
  • [3] Gotlib J. Eosinophilic disorders: Molecular pathogenesis, new classification and mofern therapy. Best practice & Reasearch Clinical Haematology. 2006;19(3):535–569 http://dx.doi.org/10.1016/j.beha.2005.07.013[Crossref]
  • [4] Allen J.A., Paterson A., Sufit R., et al. Postepidemic eosinophilia-myalgia syndrome associated with L-tryptopan. Arthritis & Rheumatism. 2011; 63(11) 3633–3639 http://dx.doi.org/10.1002/art.30514[Crossref]
  • [5] de Araujo Guerra Grangeia T, Schweller M, Aparecida Paschoal I, et al. Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake. J Bras Pulmol. 2007;33(6):747–751 http://dx.doi.org/10.1590/S1806-37132007000600021[Crossref]
  • [6] Noakes R, Spelman L, Williamsom R. Is the L-tryptophan metabolite quinolonic acid responsable for eosinophilic fasciitis? Clin Exp Med. 2006; 6:60–64 http://dx.doi.org/10.1007/s10238-006-0096-5[Crossref]
  • [7] Hertzman PA, Clauw DJ, Duffy J. Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by eosinohilia-myalgia syndrome. Ann Intern Med. 2001; 161: 2301–2306 http://dx.doi.org/10.1001/archinte.161.19.2301[Crossref]
  • [8] Dinic-Uzurov V, Lalosevic V, Milosevic I, et al. [Current differential diagnosis of hypereosinophilic syndrome] Med Pregl. 2007:LX(11–12):581–586 http://dx.doi.org/10.2298/MPNS0712581D[Crossref]
  • [9] Petterson R, Germolec D. Toxic Oli Syndrome: Review of immune aspects of the disease. J of Immunotoxicology. 2005;2(1):51–58 http://dx.doi.org/10.1080/15476910590960143[Crossref]
  • [10] Liss M. Eosinophilia. In Medscape Reference [online]. Available at: www.emedicine.medscape.com/article/199879-overview
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-013-0339-2
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.